The Brand Name APRISTAR Has Generic Salt :: APREPITANT
APRISTAR Is From Company Lupin Priced :: Rs. 1300
APRISTAR have APREPITANT is comes under Sub class Anti Emetics of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: Anti Emetics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|APREPITANT||KIT||Rs. 1300||KIT (3 CAP)|
Indications for Drugs ::
Prevent nausea and vomiting caused by certain types of cancer medicines (chemotherapy), prevent nausea and vomiting after surgery.
Drug Dose ::
Prevention of Postoperative Nausea and Vomiting Adults PO 40 mg within 3 h prior to induction of anesthesia. Prevention of Chemotherapy–Induced Nausea and Vomiting Adults PO 125 mg 1 h prior to chemotherapy treatment on day 1 and 80 mg/day in the morning on days 2 and 3. Administer in combination with a corticosteroid and 5-HT 3 antagonist.
Coadministration of astemizole, cisapride, pimozide, or terfenadine; hypersensitivity to any component of the product.
Drug Precautions ::
This medicine could make hormonal contraceptives, eg the pill, mini-pill or patch less effective at preventing pregnancy. If you are using hormonal contraceptives, you should use an extra back-up method of contraception, eg condoms, to prevent pregnancy, both during treatment with this medicine and for two months after the last dose. Use with caution in Moderate to severely decreased liver function.
Drug Side Effects ::
To prevent nausea and vomiting caused by chemotherapy, the most common side effects include: Tiredness, nausea, hiccups, constipation, diarrhea, loss of appetite, headache, hair loss. To prevent nausea and vomiting after surgery, the most common side effects are: Constipation, nausea, itch, fever, low blood pressure, headache.
Pregnancy category ::
Drug Mode of Action ::
Aprepitant is an antiemetic which acts as a substance P/neurokinin 1 (NK1) receptor antagonist. It also enhances antiemetic activity of 5HT3 antagonists and corticosteroid.
Drug Interactions ::
Concurrent use with CYP3A4 inhibitors (e.g. clarithromycin, troleandomycin, diltiazem, verapamil, itraconazole, ketoconazole, nefazodone, ritonavir, nelfinavir) may lead to increased plasma levels of Aprepitant; concurrent use with CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, primidone, phenobarbital) may lead to reduced efficacy of Aprepitant. May decrease concentrations of CYP2C9 substrates e.g. phenytoin, tolbutamide, warfarin. May increase plasma levels of dexamethasone and methylprednisolone. May increase plasma levels of benzodiazepine (e.g. midazolam, diazepam, alprazolam). Serum concentrations of colchicine may increase with Aprepitant. May increase toxicity of chemotherapy drug metabolised by CYP3A4 e.g. docetaxel, etoposide, ifosfamide, imatinib, paclitaxel, vincristine, vinblastin. May increase levels of ergot derivatives resulting in ergotism. May reduce efficacy of oral contraceptives, use additional methods of contraception during treatment and for at least 1 mth following the last dose of Aprepitant. Potentially Fatal: May result in increased serum levels of astemizole, cisapride, pimozide and terfenadine which can lead to life-threatening torsade de pointes arrhythmias.